Guoquan Wan,Siyan Li,Qifan Tang et al.
Guoquan Wan et al.
Introduction: EZH2 forms the PRC2 complex with SUZ12 and EED. As a crucial catalytic subunit of PRC2, EZH2 modifies histone H3K27 via its SET domain, resulting in chromatin condensation and suppressing the transcription o...
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities [0.03%]
RORγt抑制剂在自身免疫性疾病治疗中的临床开发：挑战与机遇
Nannan Sun,Yonghui Wang
Nannan Sun
Introduction: Nuclear receptor retinoid-related orphan receptor gamma-t (RORγt) is a major transcription factor for Th17 cell differentiation and IL-17 production. RORγt has been considered as a promising drug target fo...
Challenges, opportunities and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 - 2023) [0.03%]
JAK抑制剂及其衍生的PROTACs(2022-2023年的)的挑战、机遇和治疗潜力
Rishi R Shah
Rishi R Shah
Introduction: Since the approval of the first JAK inhibitor, ruxolitinib, in 2011, the development of JAK inhibitors has expanded significantly, with applications spanning autoimmune diseases, cancer, and inflammatory dis...
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017-present [0.03%]
脂肪质量和肥胖相关蛋白(FTO)抑制剂的专利视角：2017年至今
Ze Dong,Yue Huang,Wenyang Xia et al.
Ze Dong et al.
Introduction: The fat mass and obesity-associated protein (FTO) catalytically demethylates RNA N6-methyl adenosine (m6A) modification, dynamically regulates gene expression in eukaryotes. Interestingly, FTO is highly expr...
A patent review of hepatitis B virus core protein allosteric modulators (2019-present) [0.03%]
乙型肝炎病毒核心蛋白别构调节剂的专利综述（2019年至今）
Shuo Wang,Feiyue Ma,Kai Tang et al.
Shuo Wang et al.
Introduction: The hepatitis B virus (HBV) core protein is a significant therapeutic target due to its essential role in HBV replication. Over the past five years, numerous structurally unique CpAMs have been patented. How...
Dong-Zhu Tu,Xue-Yan Hu,Jing-Xuan Lei et al.
Dong-Zhu Tu et al.
Introduction: Cytochrome P450 3A4 (CYP3A4), one of the most important xenobiotic-metabolizing enzymes, plays a central role in drug metabolism and acts as a key mediator in drug-drug interactions. CYP3A4 inhibitors can po...
JBI-802: the first orally available LSD1/HDAC6 dual inhibitor to enter clinical trials [0.03%]
JBI-802：首个进入临床试验的口服LSD1/HDAC6双重抑制剂
Jingya Zhang,Xiangli Ren,Yihui Song et al.
Jingya Zhang et al.
Introduction: Lysine-specific demethylase 1 (LSD1) and histone deacetylase 6 (HDAC6) are key epigenetic regulators involved in histone demethylation and deacetylation, processes that impact chromatin structure and gene ex...
P2Y12R antagonists in antithrombotic therapy: a patent and literature review (2019-present) [0.03%]
抗血栓治疗中的P2Y12R拮抗剂（2019年以来的专利和文献回顾）
Xin-Yu Chen,Kai Wang,Jie Jia et al.
Xin-Yu Chen et al.
Introduction: P2Y12 receptor (P2Y12R) is a G protein-coupled receptor that plays a crucial role in regulating platelet activation and aggregation. P2Y12R is involved in various processes such as renal fibrosis, cancer, is...
Updated patent review for Hematopoietic progenitor kinase (HPK1) inhibitors and degraders (2021-present) [0.03%]
造血祖细胞激酶（HPK1）抑制剂和降解剂的专利审查更新(2021年至今)
Ying-Hui Yuan,Jia-Ying Mao,Ji-Fan Yue et al.
Ying-Hui Yuan et al.
Introduction: Hematopoietic progenitor cell kinase (HPK1) is a serine/threonine kinase of MAP4K family. It negatively regulates T cell receptor and B cell signal transduction. The loss of HPK1 kinase function increases th...
Fahad Imtiaz Rahman,Thomas M Webster,Corey R Hopkins
Fahad Imtiaz Rahman
Introduction: Metabotropic glutamate receptor 4 (mGluR4) regulates disease by modulating neurotransmitter release and synaptic plasticity and has been implicated in various diseases, including neurodegenerative disorders ...